Back to top
more

Verano Holdings Corp. (VRNOF)

(Delayed Data from OTC)

$3.63 USD

3.63
48,821

-0.01 (-0.14%)

Updated Jul 9, 2024 12:03 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (166 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VRNOF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Verano Holdings Corp. [VRNOF]

Reports for Purchase

Showing records 81 - 100 ( 145 total )

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 81

03/02/2023

Industry Report

Pages: 9

Cannabis Industry: Monthly Performance and Valuations February ''23

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 82

02/27/2023

Daily Note

Pages: 21

U.S. MSO Cannabis 4Q22 Preview

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 35.00

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 83

02/23/2023

Industry Report

Pages: 27

Cannabis State of the Union: A Year of Resiliency With Focus on 2024

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 35.00

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 84

02/21/2023

Industry Report

Pages: 9

Weekly ReHash: 280E Removal Would Bring More Than Just Financial Leverage

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 85

02/12/2023

Industry Report

Pages: 9

Weekly Rehash: U.S. Interstate Commerce the Long Game

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 86

02/05/2023

Industry Report

Pages: 11

Weekly ReHash: Cannabis - Year of Resiliency

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 87

01/30/2023

Industry Report

Pages: 10

Weekly ReHash: Industry Preserving Cash in Prep for a Nuclear Winter

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 88

01/22/2023

Industry Report

Pages: 8

Weekly ReHash: Scoring the MSOs with Cash Flow, Debt and Valuations

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 89

01/19/2023

Industry Report

Pages: 27

2023 Outlook: Optimistic Well-Capitalized Businesses with a Clear Path to Positive FCF Should Find Their Footing

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 35.00

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 90

01/13/2023

Industry Report

Pages: 18

Cannbis Weekly

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 25.00

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 91

01/10/2023

Company Report

Pages: 6

Quality at a Discount: FCF Yield Exceeds 15% by H223

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 92

01/09/2023

Industry Report

Pages: 8

Weekly ReHash: Putting 2022 Performance & Valuations Behind Us

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 93

11/29/2022

Industry Report

Pages: 5

Cannabis Update: NY Regulations a Different Framework, Verticality Challenged

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 5.00

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 94

11/19/2022

Industry Report

Pages: 9

Weekly ReHash: 3Q Cannabis Earnings Recap, Inflationary Pressures Impacting NT

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 95

11/15/2022

Company Report

Pages: 7

Q322 Beat: Riding High on New Jersey as Margin Expansion Drives EBITDA Outperformance, Capex Slowdown Supports FCF Growth

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 96

11/15/2022

Company Report

Pages: 8

3Q22 Margin Strength on Tempered Outlook

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 97

11/15/2022

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 98

11/14/2022

Daily Note

Pages: 5

Verano Reports Strong EBITDA for Q3

Provider: VENTUM CAPITAL MARKETS

Analyst: ZANDBERG J

Price: 5.00

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 99

11/02/2022

Daily Note

Pages: 9

Q3 Fundamentals Appear Soft but Legislative Reform Looks Promising

Provider: VENTUM CAPITAL MARKETS

Analyst: ZANDBERG J

Price: 12.50

Research Provided by a Third Party

Company: Verano Holdings Corp.

Industry: Medical - Products

Record: 100

11/02/2022

Daily Note

Pages: 3

Cannabis Industry Update: 3Q22 Earnings - Week I Preview

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party